Search hospitals > Minnesota > Minneapolis
Health Partners Inc
Claim this profileMinneapolis, Minnesota 55454
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Stomach Cancer
229 reported clinical trials
9 medical researchers
Summary
Health Partners Inc is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Stomach Cancer and other specialties. Health Partners Inc is involved with conducting 229 clinical trials across 392 conditions. There are 9 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Pamala A. Pawloski, and Jessica A. Thomes Pepin.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park8 years of reported clinical research
Expert in Thyroid Cancer
Expert in Non-Small Cell Lung Cancer
104 reported clinical trials
167 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital6 years of reported clinical research
Expert in Thyroid Cancer
Expert in Cancer
61 reported clinical trials
110 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park6 years of reported clinical research
Studies Cancer
Studies Uterine Tumors
14 reported clinical trials
19 drugs studied
Jessica A. Thomes PepinAbbott-Northwestern Hospital2 years of reported clinical research
Studies Endometrioid Carcinoma
Studies Stomach Cancer
10 reported clinical trials
26 drugs studied
Clinical Trials running at Health Partners Inc
Breast Cancer
Bladder Cancer
Lung Cancer
Thyroid Cancer
Prostate Cancer
Breast cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Bladder Carcinoma
Stomach Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Health Partners Inc?
Health Partners Inc is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Stomach Cancer and other specialties. Health Partners Inc is involved with conducting 229 clinical trials across 392 conditions. There are 9 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Pamala A. Pawloski, and Jessica A. Thomes Pepin.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.